Articles tagged with Molecular Imaging
Researchers report on a new dosing regimen for actinium-225 labeled targeted alpha therapy, showing promising anti-tumor response in patients with PSMA-positive tumors. The treatment protocol balances treatment response with toxicity concerns to provide effective therapy with minimal side effects.
Theranostics combines predictive biomarkers and precise therapy to target cancer cells, minimizing side effects. The field is expected to change nuclear medicine from 'nuclear radiology' to true 'nuclear medicine,' with potential for cures.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced the recipients of the 2017-2019 Wagner-Torizuka Fellowship. The two-year fellowship provides extensive training and experience in nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. This year's fellows are Sho Mo...
A new approach to optical imaging allows for fast and economical tracking of multiple molecular interactions in large areas of living tissue. The method, developed by Rensselaer Polytechnic Institute researchers, can capture interactions in mere billionths of a second and simultaneously track 16 colors of spatially linked information.
Researchers at Case Western Reserve University have developed a new multicolor MRI method that enables simultaneous detection of two different contrast agents, allowing for immediate comparisons of diseased and healthy tissue. This breakthrough has the potential to transform molecular imaging and aid disease diagnosis.
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for hepatobiliary scintigraphy in abdominal pain. The new guidelines aim to ensure cost-effective and appropriate utilization of advanced diagnostic imaging services, helping referring physicians make informed decisions.
The Society of Nuclear Medicine and Molecular Imaging recognized Robert E. Henkin, MD, for his 30-year dedication to the field of nuclear medicine, while John M. Hoffman, MD, was honored for his expertise in molecular imaging research and leadership roles in the SNMMI Clinical Trials Network.
Researchers developed a novel imaging tracer that allows for early assessment of abdominal aortic aneurysm (AAA) risk. The study shows high sensitivity and specificity in detecting vessel wall biology, suggesting a promising tool for AAA risk stratification.
The Society of Nuclear Medicine and Molecular Imaging's Technologist Section recognized the work of several award-winning nuclear medicine technologists, including Amanda Abbott, Dusty M. York, Cindi Luckett-Gilbert, Margaret M. Doonan, and Robert A. Pagnanelli, for their contributions to education and service in the field.
Monash University researchers have identified a key part of the process by which a common clinical antibiotic is formed, paving the way for novel compounds to tackle bacterial resistance. By understanding this process, scientists can manipulate it to create modified compounds that could help combat superbugs.
A Phase II study found that increasing radiotherapy doses to hypoxic non-small cell lung cancer (NSCLC) lesions, identified by PET/CT scans, did not improve patient outcomes. The study suggests that smaller volumes of tumors with hypoxia may be more effectively targeted for radiotherapy.
Researchers have developed a novel PET tracer that can detect small blood clots in veins and arteries, providing valuable information for diagnosis and treatment. The tracer binds to GPIIb/IIIa receptors, targeting the critical molecular components involved in platelet clumping.
The Journal of Nuclear Medicine ranked 5th in impact factor among medical imaging journals, increasing to 6.646 in 2016, with a 5-year impact factor of 6.459. Citations increased to 24,977, and article influence score is 1.84.
Researchers found that dual-agent PET/MR with time of flight detects more bone metastases in breast and prostate cancer patients, improving detection accuracy and reducing radiation dose. The study used combined imaging agents <sup>18</sup> F-FDG and <sup>18</sup> F-NaF to enhance image quality.
Researchers demonstrate preclinically that dual-labeled PSMA-inhibitors improve preoperative staging and intra-operative guidance for metastatic prostate cancer patients. This combined approach results in more accurate detection of PSMA-positive tumor lesions, enhancing patient outcomes.
A new imaging test, Ga-68 PSMA PET/CT, has been shown to detect cancer that conventional imaging missed, changing treatment plans for 51% of patients. The test also improved management for patients with recurrent disease, with 69% receiving radiation therapy and 64% undergoing surgery.
A single dual time-point PET scan can identify two important biomarkers of Alzheimer's disease: neuronal injury and amyloid load. This non-invasive method shows promise for early diagnosis and personalized treatment.
A new study demonstrates the feasibility and safety of HuMab-5B1, an antibody that targets the cancer antigen 19-9, found on pancreatic tumors and other malignancies. The treatment shows promise for better identifying tumors and directing treatment.
Researchers developed a personalized peptide-receptor radionuclide therapy (PRRT) approach, which increased the radiation dose to tumors by up to three times. The treatment showed reduced side effects and improved safety profiles without compromising therapeutic benefits.
Researchers found that combining peptide-receptor radionuclide therapy (PRRT) with a PARP inhibitor significantly slows the growth of neuroendocrine tumors. The treatment combination induced more cell death and inhibited cell proliferation in both gastroenteropancreatic and bronchopulmonary NET cell lines.
The Society of Nuclear Medicine and Molecular Imaging recognized seven new SNMMI Fellows for their distinguished service and exceptional achievements in the field. The fellows include past SNMMI presidents, renowned experts, and leaders in nuclear medicine and molecular imaging.
The grants will support pre-clinical and clinical diagnostic and therapeutic research, including the development of new imaging agents and clinical trials on therapy safety and efficacy. The Brain SAFTIE initiative aims to identify gaps in existing knowledge and facilitate collaboration among experts.
Pomper is recognized for his work on developing new imaging agents targeting cancer and central nervous system processes. He oversees several federally funded programs at Johns Hopkins, advancing the field of molecular imaging.
Researchers developed a scanner that unites optical, radioluminescence, and photoacoustic imaging to evaluate thin-cap fibro atheroma (TCFA) in the earliest stages. This could lead to a paradigm shift in coronary artery disease diagnosis and assessment.
Researchers demonstrated the efficacy of targeted photodynamic therapy (tPDT) to treat prostate cancer before and during surgery, using a PSMA-targeting agent coupled with photosensitizers. The technique optimizes prostate cancer care by allowing visualization of tumors prior to surgery and providing real-time guidance to surgeons.
A study found that brain receptors involved in addiction adapt to chronic drinking by reducing their bioavailability, but return to normal after detoxification. This can serve as a predictor of long-term sobriety success.
Fowler has made significant contributions to brain research, developing the radiotracer F-18-FDG to measure brain glucose metabolism non-invasively in humans. Her work has facilitated advances in the study of the human brain and malignant tumor detection.
Experts argue against the linear no-threshold hypothesis, citing evidence of adaptive responses that repair mutations or remove damaged cells. The authors suggest that diagnostic quality and accurate information are more important than erring on the side of caution in reducing radiation exposure.
Researchers develop new protocol using PaCO2 to amplify myocardial blood flow, offering an alternative to injectable pharmacological agents. The study shows a safe and effective method for widening heart blood vessels during stress tests, benefiting patients with severe side effects from traditional methods.
Researchers have developed a new technique using Cerenkov luminescence imaging (CLI) to assess tumor margins during breast tumor surgery. This method combines optical and molecular imaging, providing high-resolution images of the tumor and surrounding tissue.
Researchers developed a dual-modality imaging technique using SPECT/CT and fluorescence to detect micrometastases in colorectal cancer. This approach can guide resection of tumor lesions and potentially improve prognosis for cancer patients.
Researchers used PET/CT scans to determine the potential effectiveness of bevacizumab treatment in children with diffuse intrinsic pontine glioma (DIPG). The study found that non-invasive imaging can help predict therapeutic potential and toxicity, paving the way for personalized medicine approaches.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria for ventilation/perfusion imaging in pulmonary embolism. The guidelines aim to promote cost-effective and appropriate utilization of advanced diagnostic imaging services, affecting approximately 300,000 Americans each year.
Cytomegalovirus has evolved to hide from the immune system by presenting decoy markers, tricking NK cells into thinking infected cells are healthy. The immune system responds by evolving new mechanisms to detect and kill the virus, including a molecule called NK1.1.
Researchers developed new engineered PET tracers to image immune checkpoint expression in cancer cells, enabling monitoring of targeted immunotherapy. The study shows practical immunoPET radiotracer design modifications and their effects on human PD-L1 immune checkpoint imaging.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for bone scintigraphy in patients with prostate or breast cancer. The new AUC aim to improve healthcare outcomes by making the use of bone scintigraphy more consistent and reducing unnecessary imaging costs.
Researchers found that Fluciclovine PET/CT significantly improved targeted therapy for recurrent prostate cancer by defining tumor-targeted areas. The treatment led to higher radiation doses to the penile bulb without increased toxicity.
Researchers develop a new PET radiotracer that can quickly identify life-threatening atherosclerotic plaques by detecting inflammation. This breakthrough has the potential to prevent heart attacks and strokes by allowing for early treatment of atherosclerosis.
Researchers at Max Planck Institute for Chemical Ecology have developed a new technique to visualize molecular distributions on rippled, hairy, or bulgy surfaces. The 'corrective glass' method uses laser ablation electrospray ionization (LAESI) to correct for surface topography and provide accurate chemical imaging.
A new gallium-68 labeled peptide BBN-RGD agent has been developed to target both gastrin-releasing peptide receptor and integrin αvβ3, providing dual-receptor targeting and advantages over single-receptor targeting. The agent has shown safety and effectiveness in detecting primary and metastatic prostate cancer lesions.
Researchers have developed an image analysis technique called Hyper-Spectral Phasor (HySP) that can track multiple molecules in living organisms, making it easier to diagnose diseases and identify therapeutic targets. The new technology uses cell phone images and is faster and less expensive than current methods.
Researchers argue that the linear no-threshold hypothesis, which suggests all radiation is harmful, is inaccurate and has led to widespread fear of low-dose radiation. Studies show that low doses stimulate protective responses, reducing cancer risk rather than increasing it.
A German multicenter study confirms the efficacy and safety of Lu-177-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer, demonstrating a positive response rate of 45% and manageable side effects. The treatment offers an additional option for end-stage patients with high response rates and low toxicity.
Molecular imaging techniques have the potential to revolutionize cancer diagnosis, monitoring, and treatment by providing non-invasive alternatives to traditional biopsies. By identifying specific biomarkers, these methods can help doctors choose the most effective treatments, minimize side effects, and predict patient outcomes.
Researchers developed low-cost 3D printed organ models of varying size and shape to aid in determining optimal dosing for individual patients. The study demonstrates the potential of 3D printing technology for clinical prototyping, particularly in quantitative SPECT/CT imaging.
A novel imaging agent, Zr-89-Df-IAB2M, has been shown to detect metastasis of prostate cancer in both bone and soft tissue lesions with high accuracy. The agent targets PSMA on the exterior of prostate cancer cells, allowing for faster and more accurate detection than conventional methods.
Researchers have successfully used PET imaging to visualize cardiac amyloidosis, a condition characterized by abnormal protein deposits in the heart. The study showed that F-18-florbetaben PET imaging can accurately identify and differentiate between cardiac amyloidosis and hypertensive heart disease.
The study demonstrates the effectiveness of activity-based probes in detecting early signs of atherosclerosis. By targeting cysteine cathepsins, the probes image activated macrophage populations using optical and PET/CT methods, providing real-time monitoring of disease progression and therapeutic responses.
Researchers developed a new radiotracer that safely and effectively maps sentinel lymph nodes in breast cancer patients. The study demonstrated the tracer's ability to provide clear SLN imaging with high detection rates.
The SNMMI-TS awarded Lynne Roy, Crystal Botkin, David Campbell, Marcia Hess Smith, Deborah Gibbs, Dmitry D. Beyder, and Aaron Scott for their exceptional contributions to the field of nuclear medicine technology, including education, service, and leadership.
SNMMI recognized Peter Herscovitch and Satoshi Minoshima for their contributions to the field of nuclear medicine through various awards. Dominique Delbeke received the Presidential Distinguished Educator Award for her work as editor of The Journal of Nuclear Medicine.
Researchers have developed a new device that enables existing breast cancer imagers to provide up to six times better contrast of tumors in the breast while maintaining the same or better image quality. The Variable Angle Slant Hole Collimator reduces radiation dose to patients by half, potentially improving imaging of other organs.
A new study by the Society of Nuclear Medicine and Molecular Imaging shows that PET/CT imaging using prostate-specific membrane antigen leads to highly accurate tumor detection and delineation, with a 67% accuracy rate.
A novel PET imaging study reveals a significant correlation between increased tau and decreased metabolic activity in the brains of living Alzheimer's patients, indicating clear signs of neurodegeneration. The study measures amyloid plaques, tau tangles, and metabolic activity using three different radiotracers.
A novel CT-based calculation method, SULps, accurately measures lean body mass using computed tomography, leading to more precise PET imaging results. This improvement enables better staging of disease and therapy monitoring in cancer patients.
The novel portable diagnostic tool offers a multi-dimensional look at the body by combining optical and gamma imaging, allowing physicians to visualize molecular data alongside surface organ images. Clinical pilot studies have shown promising results in imaging lymphatic and thyroid tissue, as well as tear ducts.
Researchers used FDG-PET imaging to monitor atezolizumab, an immune checkpoint inhibitor, in NSCLC patients. The study found that higher baseline tumor volumes were predictive of reduced patient survival, and further increase in tumor volume after treatment was associated with decreased survival.
Researchers used PET and SPECT to tailor radionuclide treatment for neuroendocrine cancer patients, reducing the risk of toxicity. The study showed that personalized dosimetry led to a significant alteration in radiotherapy doses, with some patients receiving reduced or increased doses.
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging honored Dr. H. William Strauss with the 2016 Benedict Cassen Prize for his seminal studies in cardiovascular nuclear medicine. This award recognizes his work that has greatly advanced nuclear medicine science and had a high clinical impact.